<DOC>
	<DOCNO>NCT00452127</DOCNO>
	<brief_summary>This open-label , multicenter , Phase I/II study safety escalate dos single-agent PRO131921 patient relapse refractory CD20-positive indolent NHL . The trial enroll two phase : Phase I dose-escalation portion patient indolent NHL Phase II portion enrollment additional patient follicular NHL two expand treatment cohort order expand safety database collect preliminary anti-lymphoma activity data .</brief_summary>
	<brief_title>A Trial Safety Escalating Doses PRO131921 Patients With Relapsed Refractory Indolent Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Signed informed consent Ability willingness comply requirement study protocol Age ≥ 18 year Documented history histologically confirm CD20positive follicular NHL ( Phases I II ) ; Phase I , CD20positive indolent lymphoma ( marginal zone lymphoma small lymphocytic lymphoma ) also include . Patients history CD20positive NHL mixed ( indolent/aggressive ) histology may also include Phase I recent relapse biopsy show indolent NHL Indolent lymphoma ( Phase I ) follicular lymphoma ( Phase II ) either relapse documented history response ( CR , CRu , PR ) ≥6 month rituximabcontaining regimen refractory previous rituximabcontaining regimen Bidimensionally measurable disease , least one lesion &gt; 1.5 cm large dimension Absolute B‑cell count ≥LLN screening ( Phase I ) ECOG performance status 0 , 1 , 2 For patient reproductive potential ( male female ) , use reliable mean contraception study 1 year follow last dose study treatment For female childbearing potential , negative serum pregnancy test within 14 day prior enrollment Prior use antiCD20 monoclonal antibody therapy ( rituximab radioimmunotherapy ) Prior use nonCD20targeted monoclonal antibody therapy within 6 month enrollment Current recent lymphoma treatment History severe allergic anaphylactic reaction human , humanize , chimeric , murine monoclonal antibody Evidence significant uncontrolled concomitant disease , cardiovascular disease , nervous system , pulmonary , renal , hepatic , endocrine , gastrointestinal disorder Evidence myelodysplasia myelodysplastic change bone marrow examination Untreated persistent/recurrent malignancy ( lymphoma ) Known active bacterial , viral , fungal , mycobacterial , infection A major episode infection require hospitalization treatment IV antimicrobial within 4 week screen oral antimicrobial within 2 week screen History recurrent significant infection bacterial infection Positive hepatitis B C serology Positive human immunodeficiency virus ( HIV ) serology Pregnancy lactation Central nervous system lymphoma Recent major surgery within 4 week screen , diagnostic surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>NHL</keyword>
	<keyword>Indolent</keyword>
	<keyword>Follicular</keyword>
</DOC>